© 2026 Nanjing Finechem Holdings Co., Ltd,
All Right Reserved
Research on 5-Fluoro-2'-Deoxyuridine (FdUrd) tracks back to a period when scientists searched for smarter ways to target cancer cells. In the 1950s, analogues of uracil started drawing interest because they twist the normal script of DNA synthesis. People like Heidelberger and his team created and tested molecules that tricked fast-growing cells. Out of that golden age for medicinal chemistry came not just FdUrd but a whole class of fluorinated pyrimidines that still shape cancer therapy. The drug's main story closes in on disrupting DNA synthesis—once inside a cell, FdUrd stops thymidylate synthase in its tracks, cutting off the supply of thymidine nucleotides. Without those building blocks, cells can’t keep dividing. This breakthrough pushed researchers to develop analogues, fueling ideas in chemotherapeutics. FdUrd earned a lasting place, both as a tool for basic biology and a molecule under the therapeutic spotlight.
FdUrd’s design adds a fluorine atom to the 5-position of the pyrimidine ring in 2'-deoxyuridine. This small change packs a punch, tricking enzymes that normally build DNA. FdUrd is a white to off-white crystalline powder, and it doesn't easily dissolve in water—part of what makes handling and formulation in the lab a challenge. It weighs in at just over 246 g/mol. Lab teams using it quickly learn about its sensitivity to light and moisture, a reminder that even simple storage requires attention to detail. Handling the compound, I always pay respect to its ability to slip through cell membranes and get involved in DNA, which reminds me that the details of chemistry never lie far from the biology.
Chemists and clinicians work off a common language of standards, and for FdUrd, this means a purity that usually hits above 98%, clear documentation of impurity profiles, and an insistence on tracking batch numbers. Some researchers demand low endotoxin levels for in vivo experiments, but most of my time with FdUrd involved cell culture work where these specs averaged less weight. Labeling stresses its hazardous potential and offers warnings about protective measures—good practice, since FdUrd’s toxicity extends to anyone careless with the powder. Stability relies on dry, cool storage conditions, away from light, and sometimes in a desiccator if humidity rises. Bottles carry hazard warnings and recommendations for gloves and hoods. This is standard for a substance that plays with DNA synthesis.
Preparation of FdUrd in the lab typically follows routes starting from 2'-deoxyuridine, using a fluorination reaction that swaps hydrogen at the 5-position with fluorine. Sophisticated reagents bring chemists to the fluorinated product through a few steps, and most reputable suppliers follow rigorous purification, usually via column chromatography. As for modifications, scientists often attach linker arms or protective groups to the sugar or base, designing new prodrugs or conjugates that might improve bioavailability or selectivity. The versatility of FdUrd's core structure makes it popular for new analogues, especially for those of us thinking about overcoming resistance or improving delivery profiles. Every shift in structure means another afternoon running NMR and HPLC, searching for the perfect balance between potency and stability.
5-Fluoro-2'-deoxyuridine doesn’t hide behind just one name. In some contexts, you’ll hear the shorthand FdUrd. Others stick with 5-FdU or the International Nonproprietary Name (INN) floxuridine. Each name tracks back to the same molecule and reminds anyone working with it to check synonyms in literature and experiment logs. From clinical trial writeups to chemical supplier catalogs, I’ve seen the same confusion crop up—someone missing an important data point because the naming didn’t match. Staying on top of a compound’s aliases is part of responsible science and cuts down on errors that slow down experiments or, worse, risk lives.
Lab experience quickly teaches respect for compounds targeting DNA. FdUrd isn’t just another tube on the shelf. Protective gloves, lab coats, and working under chemical hoods are nonnegotiable. Spills call for careful wipe-downs with suitable disinfectants since even tiny amounts of FdUrd can cause skin reactions. For disposal, it’s straight to designated waste collection, no shortcuts. Training for new staff gets blunt—nobody shrugs off a cytotoxic. Beyond the lab, regulators set exposure limits and demand clear documentation. The risk carries outside of research settings, too, especially during clinical administration. Those guidelines matter, not as red tape, but as reminders that powerful molecules cut both ways in human hands.
FdUrd’s impact spreads wide, but its most familiar home is in cancer research and treatment. Medical teams used it most for hepatic arterial infusion to treat liver metastases from colorectal cancer. Its direct DNA effects drew researchers in virology and cell biology to study basic mechanisms of replication and repair. Once, I ran co-culture models to look for drug resistance, and FdUrd always stood out for how brutally it suppresses thymidylate synthase, making cell lines either adapt or die. Recently, people began exploring FdUrd modifications for use as imaging agents or as part of synthetic biology circuits. Its reach extends to veterinary medicine and agricultural biotechnology in some corners, but the shadow of toxicity always limits experimental sprawl.
In the past decade, FdUrd found renewed attention as multidrug resistance rears its head again in oncology. Teams in the US and abroad take turns tweaking the molecule, hoping to slip past transport-mediated drug efflux or repair-driven resistance. Combining FdUrd with phosphonate or peptide carriers, or packing it into nanoparticles has moved from theory to early-stage trials. Genomic screening helps research groups pick likely responders or flag patients at higher risk of toxicity before treatment even begins. I remember how, not long ago, studies reporting FdUrd metabolites in different tumor models shook up assumptions about how best to dose or how to mitigate myelosuppression. Data-sharing initiatives improve transparency on adverse events and uncover previously hidden off-target effects, placing patients at the center of progress.
FdUrd’s double-edged sword remains acute myelosuppression and gastrointestinal toxicity. Animal studies and phase I trials let everyone know early that safety margins are thin. Dose adjustments help somewhat, but personalized regimens only work if clinicians have a real-time view of patient metabolism and drug interactions. Preclinical research keeps unearthing new variants—like fluorinated analogues with altered side chain chemistry—that promise less toxicity but still bring a punch to aberrant cells. Continued work on biomarkers offers real hope for predicting and preventing the nastiest side effects, but gaps linger, especially in translating lab results to population-level safety.
Anyone involved in FdUrd today knows the story isn’t done. Precision medicine invites new kinds of prodrugs tailored for tumor microenvironments or gene-edited delivery cells. Advances in drug formulation, like liposomal or hydrogel-based systems, may help buffer healthy tissue from exposure. Synthetic biologists stand ready to engineer safer, more responsive analogues, using lessons from the past to craft the next generation of DNA-targeted agents. Communication between regulatory bodies, academic labs, and industry grows tighter, chipping away at delays in getting real world data back into research. There’s momentum behind using electronic health records and big data systems to watch long-term outcomes from FdUrd, a reminder that the molecule’s story mingles science, safety, and hope. As trials stretch onward, this basic building block of modern chemotherapy keeps challenging and guiding new ideas about fighting cancer and tuning biology.
5-Fluoro-2'-Deoxyuridine sounds complicated, but at its core, it plays a major part in cancer research and treatment. Scientists figured out that this molecule, closely related to the DNA building blocks in our cells, can halt cancer cell growth. It gets its name from its chemical structure: it’s a version of deoxyuridine with a fluorine atom thrown into the mix. This small change switches up the way cells handle their genetic material.
Doctors and researchers have turned to 5-Fluoro-2'-Deoxyuridine mainly as a chemotherapy drug. It tackles tumors by disrupting DNA synthesis. Cancer cells love to divide fast—they need lots of new DNA for every round. This drug sneaks in during that copying process. The cancer cell grabs it, plugs it into its DNA, and doesn’t notice the difference right away. The end result: stalled growth and, often, cell death. Hospitals use it for certain hard-to-treat cancers, including some colorectal and breast cancers. Sometimes, it’s used directly on tumors, especially during surgery on cancers in delicate spots like the liver, so it hits the problem area more than the healthy tissue.
Beyond the clinic, 5-Fluoro-2'-Deoxyuridine thrives in research settings. Cell culture labs count on it to help manage cell populations, especially in experiments involving gene editing or hybrid cell creation. Researchers toss this drug into the mix to keep fast-growing “feeder” cells in check, so the cells they care about—the experimental ones—don’t get drowned out. I’ve seen colleagues use it while building stem cell lines. Without it, the “helper” cells would take over the dish, making it nearly impossible to run genetic studies or test potential therapies. This tool makes tricky work possible.
5-Fluoro-2'-Deoxyuridine isn’t gentle. Like most strong cancer drugs, it can damage normal cells, especially those that divide quickly, just as it does with cancerous ones. Doctors balance the dose carefully, watching for side effects like mouth sores, nausea, low blood counts, and danger to the digestive tract. Safety protocols are strict. In research settings, it gets handled in chemical hoods with plenty of protective gear. No one wants to risk accidental exposure.
Cancer isn’t simple. The disease fights back in unexpected ways. Drugs like 5-Fluoro-2'-Deoxyuridine give doctors and scientists an advantage, but not without trade-offs. Health workers train hard to limit harm to patients—dose adjustments, careful monitoring, combination therapies with rescue drugs that protect healthy tissue. On the scientific side, researchers always look for safer analogs with fewer risks or more selectivity. Some are even working on nanoparticles to deliver these drugs only to cancerous tissue, sparing more healthy cells. Smart drug design and advanced delivery aim to improve outcomes by harnessing drugs like this with greater precision.
Tools like 5-Fluoro-2'-Deoxyuridine don’t just help patients today; they guide the future of treatment and research. By understanding both their benefits and their dangers, medicine builds a foundation for better, more targeted solutions. Every step forward started in labs—every treatment on someone’s chart came from work with molecules like this one. The story of cancer research is a story of progress, patience, and constant learning.
5-Fluoro-2'-Deoxyuridine packs real weight in labs—especially where cancer research or antiviral studies run full throttle. No matter how skilled a team gets, sloppy storage habits can wreck batches and scramble results. I remember a research project in grad school. We lost a month of work after realizing somebody left the compound at room temperature for the weekend. The breakdown wasn’t visible, but the numbers in the data sure told the story.
This compound comes with a reputation for sensitivity. The stories about storage disasters usually start with heat, light, or moisture sneaking in. Chemists tend to agree: anything that breaks molecular stability will knock out the drug’s effectiveness. A fact echoed by public safety sheets and the supplier’s own advice.
Leave 5-Fluoro-2'-Deoxyuridine on a shelf in a humid room and you’re gambling with money and time. This isn’t table salt. If you want it to stick around in the same reliable form, the fridge or freezer wins every time. Stick close to -20°C whenever possible, because higher temperatures ramp up the risk of chemical changes. My old lab buddy kept a stash in his home freezer during lockdown; worked better than any makeshift solution I’ve seen.
Sunlight presents another quiet risk. Keep the vial out on the bench under bright lights and the compound can lose potency. Even the light inside a refrigerator, if the vial gets left uncovered, causes subtle damage over the weeks. That’s where amber vials or wrapping in foil come into play. Solid advice, learned the hard way after a shipment sat in a bright room for an afternoon.
Moisture can trip up the best plans. 5-Fluoro-2'-Deoxyuridine, as a powder, absorbs water straight out of the air. The result isn’t just clumping. Wetness nudges forward chemical reactions that break down the core structure. That’s why keeping everything extra dry pays off. Use desiccators, or toss in a fresh silica gel pack, and close the container tight after each sample is taken. I check containers each week for leaks or condensation. Giving the outside a quick wipe before opening also stops droplets from rolling in.
People sometimes treat the freezer like a locker—grab a vial, toss it back later, repeat. The repeated up-and-down in temperature lets the compound degrade faster. Map out sample needs before opening a new vial. Aliquoting into smaller tubes right from the start saves the original batch from repeated stress. I learned this trick from a mentor who swore by careful planning. We saved plenty of precious reagents for future work this way.
Recordkeeping rarely feels exciting, but with this compound, missing a batch date leads straight to headaches. Mark every vial with the lot number and date it hit the shelf. Cross-check often and stick with the rule: oldest stock goes first. Well-organized freezers cut down on waste and eliminate the guessing game.
Labs rely on trust—trust in equipment, trust in process, and trust in each other. Treating every vial of 5-Fluoro-2'-Deoxyuridine like it’s the last one left puts science ahead. Simple attention pays off by making sure every experiment gets a fair shot. Not everything in the lab goes as planned, but storing chemicals right gives everyone a fighting chance.
Dosage questions make a person stop and think. 5-Fluoro-2'-Deoxyuridine, or FdUrd, carries a lot of weight in research labs and, in some settings, for treating cancer. Reading labels is not enough. Doctors don’t land on a single answer by flipping through a drug manual. The real answer starts with the patient or subject—weight, overall health, liver and kidney function, the specific cancer or use, and so on. There’s never a one-size-fits-all number.
Researchers and clinicians report using FdUrd at all sorts of concentrations. The actual values swing widely. For example, in cell culture, dosing flips between nanomolar and micromolar ranges depending on the cell line and the intended effect. Clinical studies talk about intravenous infusion for colorectal or breast cancer; dosing might fall in the range of 0.1 to 1.0 mg/kg per day, but the frequency and total duration change based on the treatment regime. No one piles on a uniform recommendation without considering side effects like myelosuppression, mouth sores, or gastrointestinal distress.
Real people fill in the pages of textbooks. I’ve seen researchers battle through stacks of papers, hunting for the right dosing guideline, only to settle on a dose because of the patient in front of them. FdUrd, which blocks DNA synthesis, doesn’t treat everyone equally. One person’s cancer shudders at low doses, while another needs more. Some patients can’t clear the drug through their kidneys easily, so risk toxic buildup if doctors lean on a standard guide. Lab setting, animal studies, or clinical use, every situation pulls from a different grab bag of guidelines.
Over the years, I've talked with pharmacists, oncologists, and PhD scientists. They agree—published data only gets you so far. FdUrd can kill cancer cells, but it can just as easily cause serious bone marrow suppression or liver injury. The FDA doesn’t approve FdUrd for broad use, so doctors and researchers rely on data from closely watched clinical trials. Peer-reviewed studies form the backbone: one famous trial might show how much FdUrd knocks back tumor cells in a colon cancer patient set, while another paper highlights risky side effects at the same dose.
Safety comes from experience and from sticking with protocols. Every smart lab worker or oncologist checks current guidelines, runs regular blood counts, and listens to the patient. Only licensed professionals should make dosing decisions. Patients shouldn’t buy chemicals from the internet and experiment without guidance. In the world of research, the right dose often comes from small-scale pilot studies before a full trial, with every step logged, every effect double-checked.
To fix the confusion around FdUrd dosing, scientists and clinicians need better clinical trials and real-world data. Newer research uses genetic screening and personalized medicine to push precision. Sharing credible evidence, hearing from experienced voices, and steady FDA review can reduce risk. Everyone involved—patient, researcher, or doctor—plays a role in making sure the right dose does its job without causing harm. No shortcut replaces real expertise.
5-Fluoro-2'-Deoxyuridine—often called FdUrd or FUdR—shows up in chemotherapy protocols, where fighting cancer risks outweigh many concerns. Even then, both doctors and patients pay close attention to its baggage: the side effects can add real hardship to a tough journey.
Stomach upset and mouth sores surface early for many. I’ve watched friends enduring cancer talk about how hard it gets to eat when every bite burns, or how they dread meals because nausea never lets up. Studies from the National Cancer Institute back this up, with nausea and diarrhea ranking high in patient complaints. This becomes more than a minor inconvenience—it takes away energy and motivation, which are precious during a fight for survival.
There’s another side of this drug: bone marrow suppression. Red blood cell counts drop, and anemia starts to sap strength. White blood cells get depleted, and the body’s defense weakens. Infections pop up more easily—especially worrisome in hospitals where every germ seems eager. Platelets fall too, raising bleeding risks. Lab tests can paint a stark picture: a simple routine regimen can suddenly require transfusions or antibiotics. This kind of toll makes it tough to plan life around treatment, as every clinic visit carries both hope and uncertainty.
Fatigue doesn’t just mean tiredness. Friends on treatment describe it as a kind of full-body shutdown. This fatigue interrupts work, family life, and even hobbies that used to give comfort. European Society for Medical Oncology spotlights this constant exhaustion as a top factor lowering patient quality of life. The brain slows down too—so-called “chemo brain” clouds up concentration, causes forgetfulness, and sparks real frustration.
Longer courses or higher doses carry scarier risks: liver and kidney problems. Blood tests reveal these problems before symptoms boil over, but the anxiety never really leaves. I’ve heard caregivers quietly watching the numbers, worried about changes that might force a difficult decision. Rarely, people report rashes, hair thinning, or even heart issues. These symptoms turn up less often but matter a lot to those going through them.
Doctors and nurses don’t fight alone—pharmacists, nutritionists, and support groups form circles around patients. Managing side effects takes action, not just monitoring. Antiemetic medications keep nausea in check, and protocols exist for handling low white blood cells. Specialized mouth rinses and careful oral hygiene ease painful sores. Clear advice on food, rest, and infection prevention empowers people to stay in the driver’s seat. Even so, every story I’ve come across reminds me there is no substitute for honest conversations—between patients and their teams—when challenges appear.
Clinical trials and FDA guidance guide decision making. Oncologists weigh benefits against risks and adjust strategies as research grows. Post-treatment checkups don’t just look for cancer recurrence but also support long-term healing. Counseling and peer support make it easier to adapt life plans on the fly.
No amount of preparation erases every risk. Still, knowing what to watch for, and having a team ready to listen and respond, brings confidence. With new discoveries every year, treatments keep evolving. Every person’s experience remains unique, but together, better information and support mean fewer surprises and a little less fear.
Researchers who explore anti-cancer drugs know the struggle of balancing cytotoxic effects with solid scientific outcomes. 5-Fluoro-2'-deoxyuridine (FUdR) gets a lot of attention among scientists for good reasons. It acts as a thymidylate synthase inhibitor, arresting cells in the S-phase by disrupting DNA synthesis. In practice, that translates to clear-cut results in cell culture work, especially when you need to halt cell division or selectively remove dividing cells.
In my own cell culture work, FUdR becomes almost a routine additive when handling Caenorhabditis elegans lifespan assays. By preventing egg-laying and hatching, FUdR helps keep populations synchronized, cutting down on variables that can throw off lifespan or toxicity studies. Researchers in mammalian systems have tapped into this compound to select for stable transfectants, or to halt fibroblast growth when producing feeder layers.
FUdR’s practical appeal comes with some baggage. Standard concentrations can cause stress responses in non-target cells. It doesn’t always just kill what you want it to kill. For example, nematodes exposed to FUdR in aging studies can show altered gene expression or metabolism. One study found that FUdR exposure triggered upregulation of detoxification pathways. If investigators overlook these side effects, their results might lose relevance to natural biological processes. Like with any tool, piling on without considering off-target effects can seriously undermine data quality.
Moving to in vivo models, things become even more tangled. While cell cultures give researchers tight control, animal models turn up the noise. FUdR enters the bloodstream, interacts with organs, and changes local environments in unpredictable ways. Mice treated with FUdR showed suppressed bone marrow function, weight loss, and gastrointestinal issues. Using it in C. elegans can cause distortions in metabolism and stress response, making lifespan data or metabolic readouts less reliable.
Researchers have to make trade-offs. They want to suppress unwanted cell activity, but FUdR can push animals away from their baseline physiology. Picking a lower dose might help, yet leaves room for incomplete suppression. Leaning into high doses risks confounding toxicities. Publications rarely discuss these gray areas, but anyone who has designed an experiment with FUdR knows the headaches it brings. You run an experiment, see promising results, then catch yourself questioning whether the phenotype comes from the genetic target or from FUdR’s background effects.
The scientific literature stresses transparency. Reports need to detail dosing, timing, and side effects, not just results. Open communication with peers, including failures, keeps the research field honest. Cross-validating findings using alternative compounds or methods, like genetic knockdown or RNA interference, offers a way out of methodological ruts.
Manufacturers should offer clear guidance on batch variability and purity. Even trace contaminants can change how cells or animals respond to FUdR. A good habit is reaching out for chemical analysis certificates, sticking with reputable vendors known for transparent quality control. In today’s research world, where journals require detailed methods and stress reproducibility, sourcing reliable reagents has become mission-critical.
5-Fluoro-2'-deoxyuridine remains a powerful tool, but it doesn’t solve every problem with a one-size-fits-all approach. Its roots in chemotherapy remind us of its potency and risks. For new projects, weighing biological goals against the realities of FUdR’s action leads to smarter decisions—ones that serve researchers, patients, and the broader scientific community.
| Names | |
| Preferred IUPAC name | 5-fluoro-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidine-2,4(1H,3H)-dione |
| Other names |
5-FdUrd 5-FdU 5-Fluorodeoxyuridine Floxuridine |
| Pronunciation | /ˈfaɪˈflʊə.roʊ tuːˈdɒk.siˈjʊər.ɪˌdiːn/ |
| Identifiers | |
| CAS Number | 50-91-9 |
| Beilstein Reference | Beilstein Reference 2876247 |
| ChEBI | CHEBI:44685 |
| ChEMBL | CHEMBL1567 |
| ChemSpider | 7860 |
| DrugBank | DB00217 |
| ECHA InfoCard | 13-02-00-00794 |
| EC Number | 200-914-7 |
| Gmelin Reference | 107109 |
| KEGG | C07324 |
| MeSH | D005473 |
| PubChem CID | 4056 |
| RTECS number | XN6020000 |
| UNII | 065CJA88ON |
| UN number | UN2811 |
| CompTox Dashboard (EPA) | DTXSID2044677 |
| Properties | |
| Chemical formula | C9H11FN2O5 |
| Molar mass | 246.19 g/mol |
| Appearance | White to off-white solid |
| Odor | Odorless |
| Density | 1.69 g/cm³ |
| Solubility in water | Soluble in water |
| log P | -1.0 |
| Vapor pressure | 6.8E-9 mmHg at 25°C |
| Acidity (pKa) | 12.1 |
| Magnetic susceptibility (χ) | -33.5×10^-6 cm³/mol |
| Refractive index (nD) | 1.593 |
| Dipole moment | 4.1043 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 331.3 J·mol⁻¹·K⁻¹ |
| Std enthalpy of formation (ΔfH⦵298) | -644.7 kJ/mol |
| Std enthalpy of combustion (ΔcH⦵298) | -5766 kJ/mol |
| Pharmacology | |
| ATC code | L01BC11 |
| Hazards | |
| Main hazards | Harmful if swallowed. Causes serious eye irritation. Causes skin irritation. May cause respiratory irritation. |
| GHS labelling | GHS02,GHS07 |
| Pictograms | GHS06,GHS08 |
| Signal word | Danger |
| Hazard statements | H302, H319, H361 |
| Precautionary statements | P201, P202, P261, P263, P264, P270, P271, P272, P280, P281, P301+P312, P302+P352, P304+P340, P305+P351+P338, P308+P313, P330, P332+P313, P337+P313, P362+P364, P403+P233, P405, P501 |
| Lethal dose or concentration | LD50 oral rat 230 mg/kg |
| LD50 (median dose) | Mouse oral LD50: 150 mg/kg |
| NIOSH | QU3600000 |
| PEL (Permissible) | Not established |
| REL (Recommended) | 25 mg/kg |
| IDLH (Immediate danger) | Unknown |
| Related compounds | |
| Related compounds |
Deoxyuridine 5-Fluorouracil Floxuridine Thymidine 5-Bromodeoxyuridine |
